Abstract
Homologous recombination is almost the only way to modify the genome in a predetermined fashion, despite its quite low frequency in mammalian cells. It has been already reported that the frequency of this biological process can be notably increased by inducing a double strand break (DSB) at target site. This article presents completely chemistrybased artificial restriction DNA cutter (ARCUT) for the promotion of homologous recombination in human cells. This cutter is composed of Ce(IV)/EDTA complex (molecular scissors) and two strands of peptide nucleic acid (PNA), and contains no proteins. Its scission site in the genome is determined simply by Watson-Crick rule so that ARCUT for desired homologous recombination is easily and straightforwardly designed and synthesized. The site-specificity of the scission is high enough to cut human genome at one target site. The DSB induced by this cutter is satisfactorily recognized by the repair system in human cells and promotes the targeted homologous recombination.
Keywords: Genome manipulation, artificial restriction DNA cutter, cerium, peptide nucleic acid, homologous recombination, double strand break, phosphodiester, thymine, pcPNA strands, hypermethylation, X syndrome, fluorescent protein, green fluorescence, adenovirus vector
Current Gene Therapy
Title: Artificial Restriction DNA Cutters to Promote Homologous Recombination in Human Cells
Volume: 11 Issue: 1
Author(s): Hitoshi Katada and Makoto Komiyama
Affiliation:
Keywords: Genome manipulation, artificial restriction DNA cutter, cerium, peptide nucleic acid, homologous recombination, double strand break, phosphodiester, thymine, pcPNA strands, hypermethylation, X syndrome, fluorescent protein, green fluorescence, adenovirus vector
Abstract: Homologous recombination is almost the only way to modify the genome in a predetermined fashion, despite its quite low frequency in mammalian cells. It has been already reported that the frequency of this biological process can be notably increased by inducing a double strand break (DSB) at target site. This article presents completely chemistrybased artificial restriction DNA cutter (ARCUT) for the promotion of homologous recombination in human cells. This cutter is composed of Ce(IV)/EDTA complex (molecular scissors) and two strands of peptide nucleic acid (PNA), and contains no proteins. Its scission site in the genome is determined simply by Watson-Crick rule so that ARCUT for desired homologous recombination is easily and straightforwardly designed and synthesized. The site-specificity of the scission is high enough to cut human genome at one target site. The DSB induced by this cutter is satisfactorily recognized by the repair system in human cells and promotes the targeted homologous recombination.
Export Options
About this article
Cite this article as:
Katada Hitoshi and Komiyama Makoto, Artificial Restriction DNA Cutters to Promote Homologous Recombination in Human Cells, Current Gene Therapy 2011; 11 (1) . https://dx.doi.org/10.2174/156652311794520094
DOI https://dx.doi.org/10.2174/156652311794520094 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Pharmacotherapy in Neonatal and Pediatric Extracorporeal Membrane Oxygenation (ECMO)
Current Drug Metabolism Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Current Drug Abuse Reviews Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews The bHLH Protein Nulp1 is Essential for Femur Development Via Acting as a Cofactor in Wnt Signaling in Drosophila
Current Molecular Medicine Characterization of Proteins from Putative Human DNA and RNA Viruses
Current Proteomics Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry The Role of BMPs in Bone Anabolism and their Potential Targets SOST and DKK1
Current Molecular Pharmacology Pharmacotherapy for Premature Ejaculation
Current Drug Therapy Immunomodulatory Effects of Soybeans and Processed Soy Food Compounds
Recent Patents on Food, Nutrition & Agriculture The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Introduction to the Special Issue “Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence” and a Summary of Patents Targeting other Neurotransmitter Systems
Recent Patents on CNS Drug Discovery (Discontinued) Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Melanocortin-4 Receptor Antagonists as Potential Therapeutics in the Treatment of Cachexia
Current Topics in Medicinal Chemistry Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design MYC-mediated Synthetic Lethality for Treatment of Hematological Malignancies
Current Cancer Drug Targets Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews